Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776–84.

Article  PubMed  CAS  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

Article  PubMed  Google Scholar 

Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:100905.

Article  PubMed  CAS  Google Scholar 

Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic value of FLT3-Internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncol. 2023;41:756–65.

Article  PubMed  CAS  Google Scholar 

Liu SB, Qiu QC, Bao XB, Ma X, Li HZ, Liu YJ, et al. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer Sci. 2018;109:3981–92.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Levis M. FLT3 as a marker of minimal residual disease: time to re-think? Am J Hematol. 2017;92:329–30.

Article  PubMed  Google Scholar 

Lee JM, Park S, Hwang I, Kang D, Cho BS, Kim HJ, et al. FLT3-ITD measurable residual disease monitoring in acute myeloid leukemia using next-generation sequencing. Cancers. 2022;14:6121.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, et al. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 2022;140:2407–11.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27:5195–201.

Article  PubMed  CAS  Google Scholar 

Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114:2220–31.

Article  PubMed  CAS  Google Scholar 

Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, et al. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020;33:334–43.

Article  PubMed  CAS  Google Scholar 

Huang Q, Chen W, Gaal KK, Slovak ML, Stein A, Weiss LM, et al. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol. 2008;142:489–92.

Article  PubMed  CAS  Google Scholar 

Blätte TJ, Schmalbrock LK, Skambraks S, Lux S, Cocciardi S, Dolnik A, et al. getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. 2019;33:2535–9.

Article  PubMed  PubMed Central  Google Scholar 

Khaire NS, Kim DDH, Law AD. DNA Sequencing in adults with acute myeloid leukemia to detect residual disease prior to hematopoietic cell transplant. JAMA. 2023;330:190.

Article  PubMed  Google Scholar